Mermaid Bio GmbH

Mermaid Bio is a biopharmaceutical startup pioneering intercellular antibodies. Founded in 2022 and headquartered in Germany, the company's mission is to discover and develop breakthrough intrabodies, focusing on antibodies for intracellular targets to address unmet patient needs. What sets Mermaid Bio apart is its unique approach that links single domain antibodies (nanobodies) with advancements in drug delivery, specifically utilizing mRNA/LNP systems. This proprietary platform has the potential to revolutionize medicine production. As of now, there is no public information available regarding Mermaid Bio's last investment or the involved investors. Despite the absence of recent investment details, the industry focus of the company in biopharma and biotechnology demonstrates its alignment with areas of substantial growth and innovation within the healthcare and life science sectors. With its pioneering technology and forward-thinking approach, Mermaid Bio has the potential to make a significant impact in the biopharmaceutical landscape, catering to unmet medical needs and advancing treatment options for patients.